Inventory	12 Months Ended
Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventory	Inventory For the years ended December 31, 2017 and 2016, the Company had no inventory on hand. Inventories have historically been recorded at the lower of cost or market value, with cost determined under specific identification and on the first-in, first-out (FIFO) method. Inventories consisted of raw materials and work-in-process intended for use in the manufacture of LAVIV, which was approved by the FDA in 2011 for the improvement of nasolabial fold wrinkles in adults. Raw materials that could be used either for manufacturing pre-clinical and clinical product candidates or the production of commercial products were expensed as research and development costs when selected for use in pre-clinical or clinical manufacturing operations. As a result of the wind-down of the Company’s azficel-T operations, more fully described in Note 12, the Company wrote off all remaining raw materials and work-in-process inventories as of September 30, 2016. Total inventory write-offs of approximately $0.4 million are included in cost of product sales in the Company’s Consolidated Statement of Operations for the year ended December 31, 2016. For the year ended December 31, 2017, raw materials purchased for pre-clinical and clinical trials were charged to R&D expense as incurred.

Inventory

For the years ended December 31, 2017 and 2016, the Company had no inventory on hand.

Inventories have historically been recorded at the lower of cost or market value, with cost determined under specific identification and on the first-in, first-out (FIFO) method. Inventories consisted of raw materials and work-in-process intended for use in the manufacture of LAVIV, which was approved by the FDA in 2011 for the improvement of nasolabial fold wrinkles in adults. Raw materials that could be used either for manufacturing pre-clinical and clinical product candidates or the production of commercial products were expensed as research and development costs when selected for use in pre-clinical or clinical manufacturing operations. As a result of the wind-down of the Company’s azficel-T operations, more fully described in Note 12, the Company wrote off all remaining raw materials and work-in-process inventories as of September 30, 2016.

Total inventory write-offs of approximately $0.4 million are included in cost of product sales in the Company’s Consolidated Statement of Operations for the year ended December 31, 2016. For the year ended December 31, 2017, raw materials purchased for pre-clinical and clinical trials were charged to R&D expense as incurred.